Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313235
Status:
COMPLETED
Last Update Posted:
2013-06-13
First Post:
2006-04-10
Brief Title:
Combined Modality Treatment for Patients With Stage IV Melanoma
Sponsor:
Baylor Research Institute
Organization:
Baylor Research Institute
Study Overview
Official Title:
Combined Modality Treatment for Patients With Stage IV Melanoma Cyclophosphamide and a Dendritic Cell Vaccine Loaded With Killed Allogeneic Melanoma Cells
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test a combined treatment using cyclophosphamide and a novel dendritic cell vaccine in patients with Stage IV melanoma
Detailed Description:
A novel dendritic cell vaccine is being developed at the Baylor Institute for Immunology Research Pre-clinical studies have found that this dendritic cell vaccine is more efficient in inducing a tumor specific immunity than other dendritic cell vaccines Further studies in BIIR have been done with dendritic cells that were loaded with killed melanoma cells from a melanoma cell line treated with heat before loading Both studies have shown that DCs manufactured in this novel way were more efficient in priming the melanoma specific CD8 cells Our previous studies indicate that a portion of patients with stage IV melanoma cannot mount an immune response to tumor antigens presented on dendritic cells Also regulatorysuppressor T cells can be identified in the blood of these patients which may account for the lack of induction of T cell immunity to dendritic cell vaccines Cyclophosphamide treatments have improved antitumor immunity in humans with melanoma and a clear relationship between cyclophosphamide dosage and suppressor cell activity has been documented Therefore this trial will test a combined modality treatment using dendritic cell based vaccines in patients who have been treated with cyclophosphamide
This clinical trial will evaluate the cyclophosphamidedendritic cell vaccine in patients with Stage IV melanoma The trial will accrue a total of 33 subjects The primary goal of this trial will be to test the safetytolerabilityfeasibility of the combined modality and the rate of objective clinical responseHowever if feasibility data in the first 10 subjects demonstrate the need to adjust the dose of CPA the new dose will be tested in the next 10 subjects thereby extending the accrual to 43 subjects A 15 objective response rate will be accepted in patients with stage IV Melanoma
Patients will receive cyclophosphamide 300 mgm2 administered 24 hours prior to DC vaccinations 1 3 5 6 and 7 Each subject will initially receive 7 doses of vaccination with each individual dose being administered at weeks 0 2 4 6 10 14 and 18 A clinical evaluation of the patients will be done at weeks 10 20 Patients with progressive disease will be taken off of the study Patients with SD PR or CD according to RECIST criteria may receive 4 more vaccinations Scans and re-staging tests will be performed at scheduled intervals throughout the study
This clinical trial will evaluate the cyclophosphamidedendritic cell vaccine in patients with Stage IV melanoma The trial will accrue a total of 33 subjects The primary goal of this trial will be to test the safetytolerabilityfeasibility of the combined modality and the rate of objective clinical responseHowever if feasibility data in the first 10 subjects demonstrate the need to adjust the dose of CPA the new dose will be tested in the next 10 subjects thereby extending the accrual to 43 subjects A 15 objective response rate will be accepted in patients with stage IV Melanoma
Patients will receive cyclophosphamide 300 mgm2 administered 24 hours prior to DC vaccinations 1 3 5 6 and 7 Each subject will initially receive 7 doses of vaccination with each individual dose being administered at weeks 0 2 4 6 10 14 and 18 A clinical evaluation of the patients will be done at weeks 10 20 Patients with progressive disease will be taken off of the study Patients with SD PR or CD according to RECIST criteria may receive 4 more vaccinations Scans and re-staging tests will be performed at scheduled intervals throughout the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IND 12919 | OTHER | FDA-CBER | None |